Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Belzupacap sarotalocan in Malignant melanoma of conjunctiva: ACTRN12626000465358 Clinical Landscape Report 2026
16 September 2026
ACTRN12626000465358 clinical landscape for Malignant melanoma of conjunctiva: endpoints, sponsor, phase, geography, readouts, asset context and development w…
9 min read
Fianlimab/Cemiplimab in Melanoma, Cutaneous Malignant: NCT07527325 Clinical Landscape Report 2026
16 September 2026
NCT07527325 clinical landscape for Melanoma, Cutaneous Malignant: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
SCT-C21 in Systemic Lupus Erythematosus: NCT07538154 Clinical Landscape Report 2026
16 September 2026
NCT07538154 clinical landscape for Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Nirogacestat hydrobromide in AIDS-related Kaposi Sarcoma: NCT07539454 Clinical Landscape Report 2026
16 September 2026
NCT07539454 clinical landscape for AIDS-related Kaposi Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Autologous anti-CD19 CAR-T cells(Gustave Roussy, Cancer Campus, Grand Paris) in Idiopathic Inflammatory Myopathies: NCT07544225 Clinical Landscape Report 2026
16 September 2026
NCT07544225 clinical landscape for Idiopathic Inflammatory Myopathies: endpoints, sponsor, phase, geography, readouts, asset context and development white sp…
9 min read
Sitagliptin Phosphate in Recurrent Glioma: NCT07541781 Clinical Landscape Report 2026
16 September 2026
NCT07541781 clinical landscape for Recurrent Glioma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Gemcitabine in Diffuse Large B-Cell Lymphoma: NCT07542678 Clinical Landscape Report 2026
16 September 2026
NCT07542678 clinical landscape for Diffuse Large B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
BA-3362 in Triple Negative Breast Cancer: NCT07545122 Clinical Landscape Report 2026
16 September 2026
NCT07545122 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
EGFR/IL13Rα2 Pool-CAR T Cells(City of Hope National Medical Center) in Glioblastoma, IDH-Wildtype: NCT07544992 Clinical Landscape Report 2026
16 September 2026
NCT07544992 clinical landscape for Glioblastoma, IDH-Wildtype: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
YSCH-01 in Recurrent Glioblastoma: NCT07538128 Clinical Landscape Report 2026
16 September 2026
NCT07538128 clinical landscape for Recurrent Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Navlimetostat in Neurofibrosarcoma: NCT07549022 Clinical Landscape Report 2026
16 September 2026
NCT07549022 clinical landscape for Neurofibrosarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CT-1182 in Follicular Lymphoma: NCT07548697 Clinical Landscape Report 2026
16 September 2026
NCT07548697 clinical landscape for Follicular Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.